Emergent BioSolutions has been granted a patent for a method to synthesize phosphonate ester compounds, allowing for large-scale production with high purity and stability. The patent also covers the use of a specific morphic form of the compound to treat viral infections in subjects. GlobalData’s report on Emergent BioSolutions gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Emergent BioSolutions Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Emergent BioSolutions, LPS antibody-based anti-bacterials was a key innovation area identified from patents. Emergent BioSolutions's grant share as of February 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of viral infection using morphic form ii phosphonic acid

Source: United States Patent and Trademark Office (USPTO). Credit: Emergent BioSolutions Inc

A recently granted patent (Publication Number: US11912667B2) discloses a method for treating viral infections in subjects by administering a therapeutically effective amount of morphic Form II of phosphonic acid. This specific form is characterized by an X-ray diffraction pattern that lacks prominent peaks at certain degrees, distinguishing it from other forms. The method includes administering the compound orally, typically in tablet or capsule form, at a specific dose and purity level. The patent also covers the prevention of viral infections in subjects by the same method, particularly beneficial for immunodeficient individuals or those at risk of bone marrow toxicity from existing treatments.

The method outlined in the patent is particularly relevant for treating viral infections such as cytomegalovirus or BK virus infections in subjects, especially those undergoing organ or tissue transplantation. It addresses cases where the viral infection is resistant to current medications or when subjects experience side effects from standard treatments. By administering the morphic Form II of phosphonic acid, the patent aims to provide a more effective and potentially safer alternative for managing viral infections in vulnerable populations. The method's preventive aspect further extends its utility in protecting at-risk individuals from contracting viral infections, showcasing the potential impact of this innovation in the field of antiviral therapy.

To know more about GlobalData’s detailed insights on Emergent BioSolutions, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies